免疫检查点抑制剂相关心肌炎的临床特征与结局
该多中心注册研究纳入35例ICI相关心肌炎患者并与105例无心肌炎的ICI治疗患者对照,心肌炎患病率1.14%,中位起病34天,46%发生MACE,肌钙蛋白T≥1.5 ng/ml与MACE风险4倍增加相关,较高激素剂量与较低残留肌钙蛋白和MACE率相关。
要点
- ICI相关心肌炎患病率1.14%,中位起病34天,46%发生MACE。
- 肌钙蛋白T≥1.5 ng/ml者MACE风险增加4倍(HR 4.0)。
- 较高激素剂量与较低残留肌钙蛋白和MACE率相关。
核心结论
- ICI相关心肌炎可能比既往认识更常见,起病早、病程凶险,对较高剂量激素有反应。
主要发现
- 心肌炎患病率1.14%,中位起病时间34天(IQR 21-75天)。
- 患者年龄65±13岁,29%为女性,54%无其他免疫相关副作用。
- 病例组联合ICI治疗(34% vs 2%,p<0.001)和糖尿病(34% vs 13%,p=0.01)较对照组更常见。
- 中位随访102天(IQR 62-214天),16例(46%)发生MACE,38%的MACE发生于射血分数正常时。
- 肌钙蛋白T≥1.5 ng/ml者MACE风险增加4倍(HR 4.0,95%CI 1.5-10.9,p=0.003);89%接受激素,较低激素剂量与较高残留肌钙蛋白和较高MACE率相关。
临床怎么用
- ICI治疗期间早期监测心肌炎,尤其联合ICI治疗或合并糖尿病者。
- 肌钙蛋白T≥1.5 ng/ml提示MACE高风险,需密切监测。
- 对ICI相关心肌炎考虑较高剂量激素治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myocarditis is an uncommon, but potentially fatal, toxicity of immune checkpoint inhibitors (ICI). Myocarditis after ICI has not been well characterized. OBJECTIVES: The authors sought to understand the presentation and clinical course of ICI-associated myocarditis. METHODS: After observation of sporadic ICI-associated myocarditis cases, the authors created a multicenter registry with 8 sites. From November 2013 to July 2017, there were 35 patients with ICI-associated myocarditis, who were compared to a random sample of 105 ICI-treated patients without myocarditis. Covariates of interest were extracted from medical records including the occurrence of major adverse cardiac events (MACE), defined as the composite of cardiovascular death, cardiogenic shock, cardiac arrest, and hemodynamically significant complete heart block. RESULTS: The prevalence of myocarditis was 1.14% with a median time of onset of 34 days after starting ICI (interquartile range: 21 to 75 days). Cases were 65 ± 13 years of age, 29% were female, and 54% had no other immune-related side effects. Relative to controls, combination ICI (34% vs. 2%; p < 0.001) and diabetes (34% vs. 13%; p = 0.01) were more common in cases. Over 102 days (interquartile range: 62 to 214 days) of median follow-up, 16 (46%) developed MACE; 38% of MACE occurred with normal ejection fraction. There was a 4-fold increased risk of MACE with troponin T of ≥1.5 ng/ml (hazard ratio: 4.0; 95% confidence interval: 1.5 to 10.9; p = 0.003). Steroids were administered in 89%, and lower steroids doses were associated with higher residual troponin and higher MACE rates. CONCLUSIONS: Myocarditis after ICI therapy may be more common than appreciated, occurs early after starting treatment, has a malignant course, and responds to higher steroid doses.
引用
- Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018. PMID: 29567210. doi:10.1016/j.jacc.2018.02.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。